Novo Nordisk reports first-quarter 2026 earnings on May 6, and the market is walking into the print with unusually low expectations. Consensus cited in the source material sits around $11.1 billion to $11.3 billion in revenue, with earnings estimates clustered between $0.87 and $1.10 per share, depending on the data provider and adjustment basis. The obvious debate is simple: can Ozempic, Wegovy, and the new Wegovy pill offset pricing pressure, Eli Lilly competition, and a weaker 2026 outlook?
But that may be the wrong question.
The real issue is whether Novo can prove that lower prices are buying something valuable: durable volume growth. Management already framed 2026 as a reset year, with adjusted sales and operating profit expected to decline 5% to 13% at constant exchange rates. So this quarter matters, but the next two quarters may matter more. Investors are not just grading the print. They are grading whether Novo’s pricing pain has a credible payoff.
The Base Case Setup
The market is already modeling a difficult year. Novo’s own guidance calls for adjusted sales and adjusted operating profit declines of 5% to 13% at constant exchange rates, with U.S. operations expected to decline and International Operations expected to grow. That is a striking reset for a company that had been priced, not long ago, like the undisputed monarch of obesity medicine.
Margins are also under scrutiny. Gross margin fell to 81.0% in 2025 from 84.7% in 2024, pressured by Catalent-related amortization and depreciation, restructuring costs, promotional spend, and R&D investment. Management has been clear that lower realized prices, market-access investments, and U.S. policy effects are part of the 2026 equation.
The narrative expectation is therefore not “growth machine.” It is “prove stabilization.” Investors already know Lilly is fierce, pricing is weaker, and compounded GLP-1 alternatives remain a headache. What may be incomplete is the assumption that lower price automatically equals lower quality of earnings.
The decisive question is whether Novo can convert pricing sacrifice into patient reach.
The True Earnings Pivot
The core swing factor is Wegovy pill volume and channel mix. Not just prescriptions in isolation, but where those prescriptions come from, how much is self-pay, how much is reimbursed, and whether demand expands the market rather than cannibalizing injectable Wegovy.
Management said the Wegovy pill reached around 50,000 total prescriptions for the week ending January 23, with roughly 45,000 from self-pay, and later noted more than 170,000 people were on the pill as of the earnings call week. That is the kind of launch data investors will want updated because it directly tests Novo’s strategic pivot.
The mechanism is straightforward. If Novo shows that lower pricing and broader distribution through pharmacies, telehealth, NovoCare, and Amazon Pharmacy are expanding the obesity category, the market may begin to view margin pressure as an investment. If not, the same data will look like price erosion dressed up as access.
That distinction matters for valuation. Novo’s NTM P/E has compressed from 17.82x on March 31, 2025, to 12.86x on May 4, 2026, while NTM EV/EBITDA has moved from 12.13x to 9.95x over the same period. The multiple is no longer demanding a perfect story. It is demanding evidence that the story has not broken.
Upside Scenario: A Messy Beat With Cleaner Signals
The upside case does not require a perfect quarter. It requires Novo to show that the market’s worst fears are too harsh.
That means Q1 revenue and earnings would need to land ahead of expectations, Wegovy pill uptake would need to look durable, and management commentary would need to suggest price reductions are generating volume response. The one-off $4.2 billion 340B provision reversal may help headline reported results, but sophisticated investors will look through that. The cleaner signal would be prescription traction and confidence around access expansion.
The psychology would shift from “Novo is being squeezed” to “Novo is repricing the market on its own terms.” That is a very different investor conversation.
The stock reaction in that scenario could be constructive because positioning already appears skeptical. A beat with better-than-feared commentary could make the compressed valuation look less like a value trap and more like a reset multiple waiting for evidence. Morningstar’s view that shares trade below long-term fair value is one example of that valuation tension.
The upside surprise is not the headline beat; it is proof that the pricing reset has a volume flywheel behind it.
Downside Scenario: Volume Fails To Justify The Discount
The downside case is equally clear. Novo reports acceptable headline numbers, but the details show weak U.S. momentum, continued injectable pressure, uncertain oral durability, and no clear evidence that self-pay demand can support the economics investors need.
That would compress the narrative further. Lower realized prices would no longer look like strategic access investment. They would look like defensive discounting in a market where Lilly is setting the competitive tempo.
Investors may also be underestimating the complexity of channel mix. Management itself acknowledged uncertainty around self-pay elasticity, stay time, sourcing, cannibalization, and competitive launch effects. In plain English: Novo can see the early demand, but it does not yet fully know how sticky or profitable that demand will be.
The market could punish that ambiguity. Even after the multiple reset, Novo still needs to defend why it deserves a premium to slower-growth pharma peers. If Q1 reinforces the idea that U.S. sales are falling faster than volume can offset, the multiple may stay compressed.
What Actually Matters After The Print
The next two calls matter more than the next two trading sessions. Investors should monitor Wegovy pill persistence, reimbursed access, self-pay mix, injectable cannibalization, and management’s tone on U.S. pricing.
Pipeline updates also matter, but they are not the immediate earnings lever. CagriSema, zenagamtide, semaglutide 7.2mg, and rare disease assets can support the longer-term story, yet the 6–12 month debate is still about commercial execution in obesity. Novo has assets. The question is whether the market believes those assets can defend share and rebuild momentum.
Competitive framing will be critical. Lilly’s Mounjaro and Zepbound have already become massive revenue drivers, and oral GLP-1 competition raises the bar for Novo’s pill launch. Novo does not need to win every comparison immediately, but it needs to show it can keep expanding patient reach without hollowing out margins.
The next phase is not about whether obesity is a large market. It is about who captures the economics.
Final Thoughts
Novo Nordisk enters Q1 earnings with a bruised multiple, low expectations, and a market that is no longer willing to pay for obesity dominance on faith. The company’s valuation has already reset, with NTM P/E at 12.86x, NTM EV/EBITDA at 9.95x, and NTM EV/EBIT at 11.57x as of May 4, 2026.
That makes interpretation more important than the headline numbers. A beat may not be enough if it comes with weak channel quality or cautious commentary. A messy quarter could still work if it proves that lower pricing is converting into durable patient growth.
This earnings print is less about Q1 and more about whether Novo can turn 2026 from a reset year into a credible bridge year. The monitoring point is simple: watch volume, access, channel mix, and whether the multiple starts to believe again.
Disclaimer: We do not hold any positions in the above stock(s). Read our full disclaimer here.
